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Melanoma is one of the most aggressive neoplastic transformations and characterized by a high metastatic po-
tential. The current study was performed to assess the impact of ‘‘spleen tyrosine kinase’’ (Syk), a non-receptor-
associated tyrosine kinase, on growth and metastatic behavior of melanoma cells in vitro and in a severe combined
immunodeﬁcient (SCID)-mouse/human-melanoma xenotransplantation model in vivo. Syk was expressed in me-
lanocytes but was found to be downregulated in melanoma cells. Vector-driven expression of Syk in two different
melanoma cell lines did not inﬂuence growth speed, but significantly reduced the invasive growth potential of both
cell lines in a Matrigel assay in vitro. In a SCID-mouse/human melanoma xenotransplantation model, Syk express-
ing Mel-Juso cells exhibited delayed and reduced tumor growth. After intravenous as well as subcutaneous in-
jection of tumor cells, Syk-transfected cells formed significantly fewer metastatic tumor lesions than control cells.
The presented data deﬁne Syk as a novel regulator of metastatic behavior of melanoma cells.
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‘‘Spleen tyrosine kinase’’ (Syk) is a member of the group of
non-receptor type protein-tyrosine kinases that contains as
a specified feature two Src Homology 2 domains located on
the amino-terminal end of the protein. Syk is widely ex-
pressed in hematopoietic cells, but more recently Syk ex-
pression has been noted in multiple non-hematopoietic
tissues including the liver (Tsuchida et al, 2000), nasal ep-
ithelium (Yamada et al, 2001), and breast epithelium (Coop-
man et al, 2000). The overwhelming part of functional data
however still comes from hematopoietic cells where Syk
exerts essential functions in immunoreceptor signalling,
natural killer cell-mediated cytotoxicity or maturation of
lymphocytes (Cheng et al, 1995; Turner et al, 1995; Lin et al,
1996; Brumbaugh et al, 1997).
In breast cancer, Syk expression is absent in invasively
growing parts of the tumor. Reconstitution of Syk into Syk-
negative breast cancer cells highly reduces their invasive
potential. In a mouse model Syk-expressing breast cancer
cells formed less metastatic lesions after intravenous injec-
tion and exhibited reduced tumor growth after subcutane-
ous injection (Coopman et al, 2000). So far two different
mechanisms controlling Syk expression have been de-
scribed, either hypermethylation of its promoter (Yuan et al,
2001) or alternative splicing (Wang et al, 2003). The latter
results in a splice variant, Syk B, devoid of a nuclear local-
ization signal and inefficient in blocking the metastatic phe-
notype of breast cancer cells. Alternatively to the nuclear
translocation of Syk, a cytoplasmic Syk-regulated pathway
has been described to regulate the invasive potential of
breast cancer cells. Lack of Syk expression was associated
with increased expression of the urokinase type plasmino-
gen activator (uPA) and PI-3 kinase mediated IkBa-
phosphorylation after reexpression of Syk blocked uPA ex-
pression (Mahabeleshwar and Kundu, 2003). A correlation
between these two mechanisms, a nuclear and a cytoplas-
mic mechanism, respectively, is still missing.
In patients suffering from breast cancer Syk expression is
associated with an improved prognosis (Toyama et al,
2003). A similar correlation was found in gastric cancer pa-
tients, where hypermethylation of the Syk promoter was
mainly observed in patients with lymph node metastases
(Wang et al, 2004).
Melanoma is not only the most malignant tumor of the
skin but also one of the most aggressive neoplastic trans-
formations in humans. Although an increasing number of
lesions are detected in early stages of the disease and early
excision of the tumor is performed (Koh, 1991) there are still
a high proportion of patients diagnosed with metastatic
melanoma. The 5 y survival rates for patients with clinically
detectable lymph node metastases range from 54% to 24%
depending on the number of involved lymph nodes and
ulceration of the primary tumor (Balch et al, 2004).
Once dissemination of melanoma beyond the locoregional
lymph nodes has taken place the disease is largely incur-
able. For this reason, increased understanding of mecha-
nisms regulating the metastatic behavior of melanoma is
highly important.
The current study was undertaken to assess the expres-
sion of Syk in melanoma cells and melanocytes and to test
the impact of Syk-expression on the growth and metastatic
Abbreviations: SCID, severe combined immunodeficient; Syk,
spleen tyrosine kinase; uPA, urokinase type plasminogen activator
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behavior of melanoma cells in vitro and in a severe com-
bined immunodeficient (SCID)-mouse/human-melanoma
xenotransplantation model in vivo.
Results
A 72 kDa band correlating to Syk was readily detected by
immunoblotting in three different batches of human me-
lanocytes and in a batch of Epstein–Barr virus transformed
B lymphocytes that was used as a positive control. In me-
lanoma cell lines Syk was only detectable at a very low level
in SKMel-28 cells, whereas the other melanoma cells tested
(607B, 518A2, Mel-Juso, A375, MH, BO, FB, SB) were
negative for Syk (Fig 1).
518A2 cells, grown from a melanoma metastasis, Mel-
Juso cells, derived from a primary tumor and SKMel-28
cells were stably transfected with either an expression vec-
tor (pcDNA3.1-Zeo(þ )) containing Syk cDNA (518-syk,
Juso-syk, SK28-syk) or with the vector alone (518-zeo,
Juso-zeo, SK28-zeo). The selected clones exhibited similar
expression levels of Syk and six clones from each group
were pooled to avoid subcloning artifacts (Fig 2).
To observe if the expression of Syk had any effect on the
growth speed of the transfected cells, an MTS growth assay
in 96-well plates was performed. Only a very small differ-
ence was observed between 518-zeo and 518-syk cells
(Fig 3B) and no difference in the amount of cell growth was
seen between zeo and syk cells derived from Mel-Juso and
SKMel28 (Fig 3D and F). In contrast a clear difference was
observed in a Matrigel invasion chamber assay. Transmi-
gration of Mel-Juso cells upon addition of 2% serum to the
lower chamber of the assay system was reduced by
 90% in Syk expressing cells (Fig 3C, Juso-sykþFCS)
as compared with the empty vector control cells (Juso-
zeoþFCS). Whereas Juso-zeo and Juso-syk cells had only
a very small amount of transmigrating cells without serum
addition to the lower chamber (Fig 3C, Juso zeo and Juso
syk–FCS), 518A2 derived transfectants exhibited sponta-
neous transmigration even in the absence of a chemotactic
gradient (Fig 3A, 518-zeo and 518-syk–FCS). Addition of
serum doubled the number of transmigrating cells (518-zeo
and 518-sykþFCS). Under both conditions, the number of
transmigrating cells was reduced by about 50% upon ex-
pression of Syk. A similar reduction in the number of trans-
migrating cells between vector control and Syk expressing
cells was observed for SKMel-28-derived cells in the pres-
ence of FCS (Fig 3E).
In breast cancer cells, Syk negatively regulates the ex-
pression of the uPA by blocking activation of nuclear factor
kB (NfkB). No change in the amount of phosphorylated IkBa
(Fig 4C, P-IkBa) or the subcellular location of p65 (RelA,
data not shown) between wild–type (wt), vector control or
Syk-transfected cells was observed. We performed a real-
time-PCR to assess the amount of uPA–mRNA in Syk-,
vector-transfected and wt 518A2, Mel-Juso and SKMel28
melanoma cells. uPA levels were significantly higher in
518A2 cells. Mel-Juso and SKMel28 cells expressed less
than 0.02%, 02% of uPA as compared with 518A2 (Fig 4B,
bars 518-wt, Juso-wt, SK28-wt), and uPA was not detect-
able in melanocytes (bar normal human epidermal me-
lanocytes (NHEM)). A significant difference was seen
between 518-zeo and 518-syk cells (p¼0.037) whereas
the difference between 518A2 wt cells (518-wt) and 518-syk
did not reach significance (p¼ 0.109). Whereas Mel-Juso
cells expressed uPA only at a very low level, the difference
between Juso-zeo and Juso-syk was significant (p¼0.05)
and the difference between Juso-wt and Juso-syk was not
significant (p¼ 0.618). No significant difference in uPA
expression was seen between wt and syk- or vector-
transfected cells from the SKMel28 cell line (SK28-zeo vs
SK28-syk p¼ 0.513; SK28-wt vs SK28-syk p¼0.774). A
real-time PCR for Syk performed from the same samples
confirmed the results observed in the immunoblots, namely
Syk expression in melanocytes but no expression of Syk in
the respective melanoma wt cells (Fig 4A, bars 518-wt,
Juso-wt, SK28-wt, NHEM).
To check if Syk expression has an influence on the ac-
tivation of the p42/44 MAP-kinase pathway, an immunoblot
specific for the phosphorylated isoform of p42/44 MAP-
Figure 1
Syk is expressed in melanocytes but not in melanoma cells. (A, B)
Expression of spleen tyrosine kinase (Syk) in four different populations
of normal human melanocytes (normal human epidermal melanocytes
(NHEM) 2489, 6083, 4589 and neonNHEM) and nine human melanoma
cell lines (607B, 518A2, SKMEL-28, Mel-Juso, MH, BO, FB, SB and
A375). Epstein–Barr virus transformed B cells (EBV-B) were used as
positive control. A polyclonal rabbit anti-Syk antiserum was used for
the immunoblot.
Figure2
Syk expression in vector-control- and Syk-transfected melanoma
cells. Expression of spleen tyrosine kinase (Syk) in 518A2, Mel-Juso
and SKMel28 cells stably transfected with either an empty vector (518-
zeo, Juso-zeo, SK28-zeo) or the same vector containing the Syk se-
quence (518-syk, Juso-syk, SK28-syk). A polyclonal rabbit anti-Syk
antiserum was used for the immunoblot.
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kinase was performed. No difference in MAP-kinase activity
between controls and Syk transfectants was observed
(Fig 4C, P-p42/44MAPk and p42/44MAPk).
We furthermore tested the effects of Syk expression on
tumorigenity and metastatic potential of human melanoma
cells in a SCID-mouse/human-melanoma xenotransplanta-
tion model. Vector control and Syk-expressing cells derived
from Mel-Juso and 518A2 cells were either injected subcu-
taneously (sc-groups) into the right flank or intravenously
into the animal’s tail vein (iv-groups). The primary aim in the
sc-groups was to observe if expression of Syk would
change the incidence and latency of tumor development.
Mice that had received Juso-zeo cells formed palpable
tumors 12 d after injection. In contrast, tumor formation by
Juso-syk cells was first observed after 21 d (Fig 5A). Using
518-zeo and 518-syk cells the time point of tumor take was
similar, as the first palpable tumors were observed in both
groups 12–14 d after injection. The 518A2 derived transfect-
ants formed larger tumors as compared with the Mel-Juso-
derived cell lines, but both groups demonstrated significant
differences in tumor size between vector control and Syk-
transfected cells (Fig 5B), indicating that Syk-derived cells
have a reduced ability of tumor formation and tumor growth
in an in vivo system.
To assess the metastatic potential of the transfected cell
lines, 0.5  106 cells were injected via the tail vein into SCID
mice. The experiment was ended after 40 d when mice in
the 518-zeo group developed distress. The lungs, heart,
kidneys, spleen, liver, and inguinal lymph nodes were par-
affin-embedded and the mean number of metastases was
calculated from five representative HE-stained sections. All
mice injected with 518-zeo cells and five of six mice inject-
ed with 518-syk cells exhibited metastatic tumor spread.
The mean number of metastases was 107  30 (mean 
SD) for 518-zeo versus 55  29 for 518-syk (n¼ 6;
p¼0.029) (Fig 6A, lanes zeo iv, syk iv). Juso-zeo cells
formed metastases in ten of 12 mice with up to 70 lesions in
a single animal. In contrast Juso-syk cells formed no more
than three metastases per mouse in eight of 12 animals
(Fig 6B, lanes zeo iv, syk iv). The mean number of met-
astases was 20  22 (mean  SD) for Juso-zeo versus
1  1 for Juso-syk (n¼12; p¼0.009).
Internal organs from mice in the groups with subcutane-
ous tumors were also assessed for metastatic tumor
spread. In mice with tumors from 518-zeo and 518-syk
cells, a high number of micrometastases (consisting of three
to a maximum of 10 cell layers) was observed in the liver. To
calculate the number of metastases in the liver of these
animals, 10 fields of view with a  100 magnification were
counted on the HE-stained sections and the mean number
of micrometastases per field of view per mouse was de-
picted separately from metastases in other organs (Fig 6A
lanes ‘‘sc liver’’ and ‘‘sc non-liver’’). The mean number of
liver metastases was 84  47 for 518-zeo versus 11  3 for
518-syk (n¼ 6; p¼ 0.005). The mean number of metastases
in all other organs was 11  4 for 518-zeo versus 3  2
(n¼6; p¼0.002) for mice bearing 518-syk tumors
(mean  SD).
Reflecting the difference between a cell line derived from
a primary tumor and a metastasis, the groups with subcu-
taneously injected Mel-Juso transfectants formed sig-
nificantly less metastases than 518A2 cells but still dem-
onstrated a difference between vector control and Syk ex-
pressing cells. The mean number of metastases was 6  7
for Juso-zeo versus 1  1 for Juso-syk (mean  SD, n¼ 12,
p¼0.023). Hence, our data show that the expression of Syk
Figure 3
Syk expression reduces the invasive
potential of melanoma cells in vitro.
(B, D, F) MTS assay with spleen tyrosine
kinase (Syk) expressing (518-syk, Juso-
syk, SK28-syk) and vector control (518-
zeo, Juso-zeo, SK28-zeo) cells. Numbers
are presented as % of the cell number of
the first day after plating the cells. The
assays were performed in groups of six;
the bars represent SD. (C, D) Transmi-
gration of melanoma cells in a Matrigel
assay with either plain medium (groups
FCS) or medium containing 2% serum
(groupsþFCS) in the lower chamber of
the assay system. Bars represent the
number of cells that migrated through the
Matrigel layer onto the lower side of the
perforated upper chamber. Vector control
cells in the þFCS group were set as
100%. Columns present the mean num-
bers of three independent experiments,
and bars represent SD.
SYK AND METASTATIC BEHAVIOR OF MELANOMA 1295124 : 6 JUNE 2005
not only influences the growth of tumor lesions after sub-
cutaneous and intravenous injection but also controls the
formation of spontaneous metastases from an established
tumor grown from human melanoma cells in vivo.
Discussion
Patients suffering from human melanoma rarely succumb
because of local effects of the primary tumor but usually
because of a progressive loss of organ function from met-
astatic tumor growth. Metastatic growth itself is a multistep
process, and some of the mechanisms controlling this
process have been elucidated.
In our work, we describe the influence of the non-recep-
tor-associated tyrosine-kinase Syk on the metastatic be-
havior of melanoma cells. The complete loss or substantial
downregulation of Syk-expression in all melanoma cells as
opposed to its higher expression in melanocytes indicates
that Syk is downregulated in the process of melanoma
oncogenesis. The difference in metastatic potential ob-
served after vector-derived reconstitution of Syk expression
in two of the melanoma cell lines indicates that Syk is a
negative regulator of metastatic behavior in melanoma cells.
These results were observed only in the ‘‘three-dimension-
al’’ Matrigel-assay system, but no difference in cell prolif-
eration in a ‘‘two-dimensional’’ culture plate was observed.
This correlates well with results observed under similar
conditions in breast cancer cells (Coopman et al, 2000).
Whereas Syk positive tumor cell lines have been described
for breast cancer all melanoma cell lines tested were neg-
ative for Syk, irrespective of whether they were derived from
a primary tumor, a lymph node, subcutaneous or distant
metastasis. This implies that loss of Syk expression is a
basic mechanism influencing the metastatic behavior of
melanoma cells and that further mechanisms add to the
final metastatic potential of the cells.
In 518A2 transfectants, transmigration of cells in the ab-
sence of a chemotactic gradient was inhibited as well by the
expression of Syk. This, together with the lack of an effect
on growth speed, leads to the conclusion that the effect of
Syk must be targeted to the process of active transmigra-
tion and does not impinge on pathways regulating the re-
action to chemotactic signals or cell cycle progression. Syk-
dependent regulation of uPA, a secreted enzyme enabling
degradation of extracellular matrix (Sidenius and Blasi,
2003), via the NfkB pathway was demonstrated in MCF-7
and MDA-MB-23 breast cancer cell lines (Mahabeleshwar
and Kundu, 2003). In contrast to breast cancer, none of the
melanoma cells expressing Syk after transfection, despite
having a clearly reduced metastatic potential, showed any
change in the phosphorylation of IkBa. Expression of uPA
showed statistically significant differences between vector
control and Syk-transfected cells in two of the three cell
lines investigated (518A2, Mel-Juso). However several fac-
tors argue against a role of uPA expression as the under-
lying mechanism in melanoma cells: (I) the difference was
only significant between vector control and Syk-transfected
cells but not between wt and Syk-transfected cells, (II) one
cell line (SKMel-28) did not exhibit changes in uPA expres-
sion despite clearly changing its invasive potential after Syk
transfection, (III) the extent of uPA regulation did not show a
consistent correlation with the high differences seen in Syk
expression between control and Syk-transfected cells, (IV)
the overall level of uPA was very low in SKMel-28 and Mel-
Juso cells as compared with 518A2 cells making a major
contribution of uPA in these cells questionable, and (V) the
different levels of uPA in the wt cells did not correlate to the
Figure 4
Syk does not regulate uPA expression,
1kBa-phosphorylation or phosphoryla-
tion of p44/42 MAP-kinase in melanoma
cells. (A) Quantification of spleen tyrosine
kinase (Syk)- and urokinase type plasmino-
gen activator (uPA)-mRNA in melanocytes
(normal human epidermal melanocytes,
NHEM) and in wild-type-(-wt), vector con-
trol-(-zeo) and Syk-transfected-(-syk)
518A2, SKMel28 and Mel-Juso cell lines
by real-time PCR. Results are expressed in
percentage relative to 518 syk. (B) Western
blot with antibodies specific for phosphory-
lated and unphosphorylated p42/44 MAP-
kinase (lanes P-p42/44MAPk and p42/
44MAPk) as well as phosphorylated and
unphosphorylated IkBa (lanes P-IkBa and
IkBa) in wild-type-(-wt), vector control-
(-zeo) and Syk-transfected-(-syk) 518A2,
SKMel28 and Mel-Juso cell lines. Syk ex-
pression is shown in the upper lane.
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missing differences in Syk expression between these cells.
Taken together this indicates that other pathways regulating
active transmigration might be regulated by Syk in me-
lanoma. Activation of the p42/44 MAP-kinase, another
important pathway that regulates tumor progression, ex-
pression of matrix metalloproteases and tumor angiogen-
esis in melanoma (Cohen et al, 2002; Govindarajan et al,
2003), was however also not regulated by Syk expression in
melanoma cells.
The in vitro results are substantiated by the results from
the in vivo experiments. Juso-syk cells exhibited a delayed
tumor take and reduced tumor size after subcutaneous in-
jection into SCID mice. In contrast, the time point of tumor
take was similar between 518-zeo and 518-syk cells, which
might reflect their higher ‘‘basal’’ invasive potential that was
observed in the in vitro assays. Despite this, the tumor vol-
ume was also significantly smaller in the Syk expressing
cells. A model system that could explain both observations
(the delayed tumor take as well as the reduced tumor
growth) is that secretion and activation of matrix degrading
enzymes and subsequent ‘‘remodelling’’ of the tumor envi-
ronment is an essential prerequisite for local tumor growth
(Hendrix et al, 2003; Hendrix et al, 2003). It would therefore
not only influence the time point of tumor establishment but
also exert an ongoing influence on tumor growth.
In both cell systems, the number of metastases was
significantly reduced in Syk-expressing cells after intrave-
nous injection of tumor cells into the tail vein of SCID mice.
The difference in the mean number of metastases was sim-
ilar to the difference observed in invasive potential in vitro.
Notably, a difference in the number of metastases was also
observed after spontaneous tumor spread in mice bearing
subcutaneous tumors thereby further supporting the role of
Syk as a regulator of melanoma metastases formation.
This is a report that the non-receptor-associated tyrosine
kinase p72 Syk is a regulator of the metastatic behavior of
melanoma cells. Additionally, the presented data suggest
that loss of Syk expression that up to now was described in
breast and gastric cancer, might be a more general phe-
nomenon in malignant disease. Ongoing work will have to
Figure 5
Syk-expression leads to reduced tumor growth after subcutaneals
injection of melanoma cells in SCID-mouse xenotransplantation
model. (A, B) Tumor volume of subcutaneous tumors formed after in-
jection of either spleen tyrosine kinase (syk) expressing (Juso- and 518-
syk) or vector control (Juso- and 518-zeo) cells into the right flank of
severe combined immunodeficient mice. Values represent the mean
tumor volume per group  SD. Values in the Syk groups marked with 
were significantly different from the respective vector control cells by
paired student’s t-test.
Figure6
Syk-expression is associated with a reduced number of metas-
tases in a SCID-mouse xenotransplantation model. (A, B) Number of
metastases in severe combined immunodeficient mice after iv injection
of either spleen tyrosine kinase (Syk) expressing or vector control me-
lanoma cells (zeo iv, syk iv) as well as in mice bearing subcutaneous
tumors from these cells (zeo sc, syk sc). Lines represent the mean
number of metastases in each group. Because of a high number of
micrometastases in the livers of mice with subcutaneous tumors
formed by 518-zeo or 518-syk cells, these were depicted separately as
the mean number of lesions from 10 fields of view in a  100 mag-
nification (zeo sc liver and syk sc liver).
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focus on identifying further cellular pathways that are as-
sociated with Syk influence on metastases.
Materials and Methods
Tumor cell lines 518A2, 607B (courtesy of Dr Peter Schrier,
Leiden, the Netherlands), SKMEL-28, A375 (ATCC), Mel-Juso
(German Collection of Microorganisms and Cell Culture, DSMZ,
Braunschweig, Germany) FB, MH, SB, BO (isolated from a nodular
primary tumor (MH), subcutaneous metastasis (SB), ovaric metas-
tasis (FB) and lymph node metastasis (BO) and characterized for
their expression of S100, HMB45 and Tyrosinase) melanoma cells
were maintained in Dulbecco’s mofified Eagle’s medium (DMEM)
(Invitrogen, Carlsbad, California) supplemented with 8% heat-in-
activated FCS. NHEM were obtained as cryopreserved cells from
Clonetics/Cambrex (East Rutherford, New Jersey). NHEM were
maintained in MBM-2 medium supplemented with the MGM-3
bullet kit (all Clonetics) and were used between the third and sixth
doubling after thawing. 518A2, SKMel-28 and Mel-Juso cells were
transfected with the human Syk cDNA containing mammalian ex-
pression vector pcDNA3.1-Zeo(þ ) that was kindly provided by
Professor Susette C Mueller (Georgetown University Medical Cen-
ter, Washington). Cells were transfected using a cationic lipid (Lip-
ofectin, Invitrogen) according to the manufacturers instructions.
Four hundred microgram per mL Zeocin (Invitrogen) was used for
selection of transfected cells that were tested for Syk expression
by western blotting. To avoid subcloning artifacts, six individual
clones were pooled.
Western blot Samples were prepared using a buffer containing
150 mM NaCl, 1% NP 40%, 0.5% deoxycholic acid, 0.1% SDS, 50
mM Tris, 2 mM PMSF, 2 mM Na3O4V and complete protease in-
hibitors (Roche Diagnostics, Basel, Switzerland). Western blots
were performed using 30 mg of protein. Prior to application protein
lysates were cooked at 951C for 10 min in equal volumes of a 2 
loading buffer (30 mM Tris, 12.5% glycerol, 1% SDS, 12.2 mM
mercaptoethanol, 0.5% bromophenol blue). Proteins were blotted
onto a nitrocellulose membrane. Ponceau-red stain and an anti-
body directed against b-actin were used as loading controls. An-
tibodies used were: anti-Syk rabbit polyclonal (N19, Santa
Cruz Biotechnology, Santa Cruz, California), anti–[phospho p42/
44 MAP-kinase mouse monoclonal, anti-p42/44 MAP-kinase rabbit
polyclonal (Cell Signaling, Beverley, Massachusetts) anti-phospho-
IkBa rabbit polyclonal, anti-IkBa rabbit polyclonal and anti-actin
rabbit polyclonal (Sigma, St Louis, Missouri). To assure that none of
the differences observed between melanocytes and melanoma
cells was because of different culture conditions melanoma cells
were grown in melanocyte medium as well as in the routinely used
DMEM medium 48 h prior to harvesting. No differences were ob-
served (data not shown).
Matrigel invasion chamber assay The assay (BD Biosciences,
Bedford, Massachusetts) consists of a two-well chamber system,
where the upper chamber has a perforated bottom with a pore-size
of 8 mm, large enough to allow cells to migrate through these pores.
Overlying the perforated bottom of the upper well is an artificial
basement membrane preparation (originally derived from Engel-
breth–Holm–Swarm mouse sarcomas). 25  103 cells were plated
into the upper chamber in serum-free medium. The upper chamber
was placed inside the lower chamber which contained either se-
rum-free medium or medium with 2% FCS to create a chemotactic
gradient. After 24 h, the upper chamber was removed, Matrigel and
remaining cells were cleared by swiping with a cotton bud, and the
transmigrated cells on the lower side of the upper chamber were
fixed in 70% ethanol and stained using 0.2% crystal blue. Cells in
ten  40 fields were counted from every well and expressed as
mean  SD.
Growth assay Two thousand five hundred cells in a final volume of
100 mL were plated in 96-well plates and cell proliferation was
measured photometrically using the Cell titer 96 assay (Promega,
Madison, Wisconsin). This assay is composed of a tetrazolium
compound (MTS, Owens reagent) and an electron-coupling rea-
gent (phenazine methosulfate, PMS). MTS is bioreduced by cells
into a formazan that is soluble in tissue culture medium and ab-
sorbance of the formazan can be measured at 490 nm.
Mouse experiments All procedures involving experimental ani-
mals were performed according to protocols approved by the
committee on animal welfare of the Medical University of Vienna.
Groups of either six or twelve 7–8 wk old female, pathogen-free
C.B 17-SCID mice (Harlan-Winckelmann, Germany) were either
injected with 10  106 Syk-transfected or vector control melanoma
cells into the subcutaneous fat pad of the right flank, or 0.5  106
cells were injected intravenously via the tail vein. Animals were
sacrificed after a maximum of 50 d or when animals in one group
developed serious distress. Internal organs were explanted, fixed
in 7.5% formaldehyde, paraffin-embedded and five representative
HE-stained sections 300–500 mM apart were observed for meta-
static lesions. Tumor volume in the subcutaneous tumor groups
was calculated by the formula [(largest diameter  (smallest
diameter)2)  1/6p] and depicted as mean tumor volume per
group  SD. Results of Syk transfectants and vector controls
were compared for significance using the t-test. A pp0.05 was
considered as statistically significant.
Real-time RT-PCR Primers for SYK and uPA as well as for human
glyceraldehyde 3-phosphate dehydrogenase as endogenous con-
trol were ordered from Applied Biosystems (Foster City, California)
(SYK: Hs00374292_m1; uPA: Hs00170182_m1). ABI PRISM 7700
Sequence Detection System was used for amplification and de-
tection. Reactions were performed in 20 mL and standard thermal
cycler conditions were chosen with 2 min 501C; 10 min 951C; 45
cycles 15 s 951C, 1 min 601C. Three independent experiments
were conducted. To check whether the primers are applicable to
multiplex PCR (target and endogenous control amplified in the
same tube) for both SYK and uPA separate and multiplex reactions
were processed simultaneously. No non-specific products were
detected in multiplex PCR permitting its use in subsequent anal-
yses. Reverse transcription negative controls (RT minus, isolated
RNA without reverse transcriptase) were also subjected to PCR to
rule out target amplification from genomic DNA contamination. For
relative quantitation of gene expression, comparative CT method
was selected (as described in ABI User Bulletin #2, p11ff. http://
docs.appliedbiosystems.com/pebiodocs/04303859.pdf).
Statistical analysis was performed by paired t-test.
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